TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest update is out from Senti Biosciences ( (SNTI) ).
On July 18, 2025, Senti Biosciences announced the appointment of Bryan Baum to its Board of Directors, increasing the board size from seven to eight members. Baum, a seasoned entrepreneur and investor, brings extensive experience in founding and scaling successful companies, which Senti Bio believes will be instrumental in advancing its Gene Circuit programs. His appointment is expected to enhance the company’s strategic direction and optimize value for stakeholders as it continues to develop innovative cancer therapies.
The most recent analyst rating on (SNTI) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Senti Biosciences stock, see the SNTI Stock Forecast page.
Spark’s Take on SNTI Stock
According to Spark, TipRanks’ AI Analyst, SNTI is a Neutral.
Senti Biosciences is currently facing significant financial challenges, with ongoing losses and high leverage being the most critical issues. While technical analysis suggests some positive momentum, the overall valuation is weak due to negative earnings. However, recent corporate events, such as promising trial data and strategic leadership changes, provide a positive outlook, offering potential upside if financial stability can be improved.
To see Spark’s full report on SNTI stock, click here.
More about Senti Biosciences
Senti Biosciences, Inc. is a clinical-stage biotechnology company focused on developing next-generation cell and gene therapies using its proprietary Gene Circuit platform. The company aims to engineer Gene Circuits into new medicines with enhanced precision and control, targeting challenging liquid and solid tumor indications. Senti Bio’s technology has shown potential in preclinical studies to work in both NK and T cells, and the company is advancing these capabilities through partnerships.
Average Trading Volume: 345,583
Technical Sentiment Signal: Sell
Current Market Cap: $51.38M
For detailed information about SNTI stock, go to TipRanks’ Stock Analysis page.